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ABSTRACT
The main objective of this presentation is to review current knowledge regarding molecular mechanisms 
of Transforming Growth Factor-E1 (TGF-ß1) action in breast carcinogenesis. In addition, our recent 
results will be presented on TGF-ß1 gene polymorphism and its relationship to TGF-ß1 secretion in 
breast cancer (BC) patients. Special focus will be made on potential clinical applicability of TGF-ß1 as a 
putative diagnostic, prognostic or predictive tool in BC detection and treatment. TGF-ß1 has a complex 
multifunctional profile, with tumour suppressive effects in early stages of breast carcinogenesis, but 
progressive dominance of tumour promoting effects with transition to more advanced malignant states. 
Clarification of molecular mechanisms that control parallel processing of these opposing TGF-ß1 activi-
ties might suggest new approaches for shifting the balance in favour of net tumour suppression. Now, a 
major challenge remains in more precisely defining TGF-ß1 signalling pathways and their cancer-related 
alterations. Current dogma views human tumorigenesis as a molecular disruption of normal physiology 
through genetic, epigenetic, or somatic alterations. The genetic model offers biological plausibility to 
epidemiological studies that link the TGF-ß1 gene polymorphism, at codon 10 due to Leu10Pro substi-
tution in the signal peptide, with the risk of developing BC. The somatic mutations approach, provides 
an explanation for the TGF-ß1 overexpression in advanced BC through mutations acquired in the com-
ponents of Smad-mediated TGF-ß1 signalling pathway. The available results indicate decreased TßRII 
(TGF-ß1 receptor-type II) expression, rare TßRII gene mutations, but no mutations in Smad2 and Smad4 
genes, in advanced BC patients.
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INTRODUCTION
D
espite increased awareness and earlier detection, large percentage of breast cancer 
(BC) diagnosed women die from metastatic disease each year. Furthermore, treatment 
regimens for fighting advanced disease have significant side effects including cardiotoxic-
ity, neurotoxicity, and secondary cancers. A better understanding of BC biology and the 
mechanisms of drug therapies should allow for more selective and less toxic treatments(1). 
Due to the morbidity associated with chemotherapy, there is a demand for molecular mark-
ers that can provide a more accurate prognosis and predict response to therapy (2,3). At 
the present time Transforming Growth Factor-E1 (TGF-ß1) is being evaluated as potential 
candidate for such biomarker, although its diagnostic role in BC has not been established 
yet (4). This communication covers literature survey on current knowledge regarding 
TGF-ß1 molecular mechanisms of action in breast carcinogenesis. In addition, some of the 
recent results from our laboratory will be presented. Special focus will be made on potential 
clinical applicability of TGF-ß1 as a putative diagnostic, prognostic or predictive tool in BC 
detection and treatment.
TGF-ß1 ACTS BOTH AS TUMOUR SUPRESSOR AND AS TUMOUR
PROMOTER
TGF-ß1 has an important role in normal mammary biology as a potent regulator of mammary 
epithelial proliferation, mammary ductal and alveolar development, and postlactation involution 
of the mammary gland. The TGF-ß1 signalling pathways also have an important role in human 
mammary carcinogenesis revealing dual function of TGF-ß1 in this process (4). In healthy 
tissue, premalignant, and early-transformed states, TGF-ß1 might act mainly as an epithelial 
growth inhibitor. As cells progress along the neoplastic continuum, these regulatory mecha-
nisms become compromised because of a loss of negative cell signalling or because of a 
fundamental change in the TGF-ß1 switch. The net result of these pathophysiological changes 
is a loss of growth inhibition and concomitant stimulation of growth promotion in the process 
of tumour progression. Consequently, tumours that are further advanced generally express 
more TGF-ß1 , which has been correlated with a more malignant phenotype and impaired 
clinical outcome. Therefore, a major challenge remains to precisely define TGF-ß1 molecular 
mechanisms of action in the process of carcinogenesis (5). Current dogma views human 
tumorigenesis as a molecular disruption of normal physiology through genetic, epigenetic, or 
somatic alterations (4-6). The genetic model offers biological plausibility to epidemiological 
studies that link TGF-ß1 polymorphism with risk of developing breast cancer. There is grow-
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TGF-E1 in breast cancer
ing evidence that common variants of  TGF-ß1 gene may affect the production, secretion, or 
activity of this cytokine. Now, five different TGF-ß1 gene polymorphisms have been identified 
with respect to BC risk (7). Among these, the most extensively studied is the TGF-ß1 gene 
polymorphism at codon 10 due to Leu10Pro substitution in the signal peptide (8-10).
LEU10PRO TGF-B1 POLYMORPHISM
Previous reports have analyzed relationship between the Leu
10Pro TGF-ß1 polymorphism 
versus progressive BC stages or survival of BC patients. The obtained results indicate that 
the Pro
10 homozygotes have an increased incidence of invasive BC (9) and significantly 
decreased BC patients’ survival (10). In addition, increased plasma levels of TGF-ß1 protein 
were observed in Pro
10 homozygotes when compared to Leu
10 homozygotes or Leu
10Pro 
heterozygotes in a general population (11). Moreover, Dunning and co-workers (9) have 
shown that the allele encoding Pro
10 is associated with increased rates of TGF-ß1 secretion
in advanced BC patients. However, this and other studies (8) have excluded cases with early 
stages of BC whose genetic susceptibility might considerably contribute to the evaluation of 
plasma TGF-ß1 DVDSURJQRVWLFIDFWRUIRUWKH6WDJH,,,GLVHDVH
Therefore, we have investigated the role of plasma TGF-ß1LQSURJQRVLVRIHDUO\6WDJH,,,
BC patients and possible relevance of genetic variants that affect TGF-ß1 production and 
secretion. Concentration of TGF-ß1 in plasma was analyzed by the TGF-ß1 receptor-type 
II (TERII) -based TGF-ß1 ELISA kit as previously described (12). Our results indicate that 
plasma TGF-B1OHYHOVRI6WDJH,,,GLVHDVHPHDQYDOXHrQJPOUDQJH
QJPOQ S!WHQGHGWREHXQFKDQJHGZLWKUHVSHFWWRQRUPDOGRQRUVPHDQ
value: 1.45 rQJPOUDQJHQJPOQ %DVHGRQFOLQLFDOSDUDPHWHUV
obtained after surgery, we have selected three early stage patients presented in Table 1, 
one with low risk (Case 1) and two with high risk prognosis (Cases 2 and 3). DNA was 
isolated from their malignant tissue samples as well as from full blood of three healthy 
donors(HD) used as controls. PCR was used to amplify for the TGF-ß1 gene fragment of 
485 bp, including the exon 1 and neighbouring parts of the surrounding sequences as 
described in the Legend to Figure 1.
Table 1. A summary of data on Leu
10Pro polymorphism  of  TGFß ß1 gene for three early stage BC patients 
relative to healthy donors (HD), as detected from DNA sequencing profiles illustrated in Figure 1
SUBJECT‘S CHARACTERISTICS DNA POLYMORPHISM
BC patient
Healthy
donor
number prognosis
Menopausal
status *
Age TGFB1 Leu
10 Pro genotype
low
risk
high
risk
premn. postmn. (years) zygocity
Case 1 + + 40 Leu
10Pro hetero
Case 2 + + 55 Leu
10 homo
Case 3 + + 75 Leu
10 homo
HD 1 + 58 Leu
10 homo
HD 2 + 51 Leu
10Pro hetero
HD 3 + 57 Leu
10Pro hetero etero
* Abbreviations: premn., premenopausal; postmn., postmenopausal.
Sequencing profiles and the respective DNA sequences for the described gene fragment 
were almost identical for all of the above samples, indicating lack of mutation in this genetic 
locus. Exception was observed at nucleotide position 29 of the amplicon. As shown in 
Figure 1, our results reveal polymorphism at codon 10 due to Leu
10Pro substitution in the 
signal peptide of TGF-ß1 with the two types of variants. Table 1 illustrates the distribution of   
TGF-ß1  Leu
10Pro genotype in BC patients (n=3) and healthy donors (n=3), with respect 
to subjects characteristics.
Figure 1. Sequence analysis illustrating presence of Leu
10Pro polymorphism in two BC patients with 
HDUO\VWDJHVRIGLVHDVH3DQHODZLWKDUURZSRLQWLQJGRXEOH&7SHDNDWWKHQXFOHRWLGHSRVLWLRQ
of codon 10, representing Leu
10Pro heterozygote (Case 1); and Panel b, arrow pointing a single T 
peak at the 29 nucleotide position of codon 10, representing Leu
10 homozygote (Case 2). Genomic 
DNA was isolated from tumour tissue obtained after surgery. Polymorphic region of TGF-ß1([RQ
485 bp in length, was then amplified using specific primers, whose sequences were as follows: 5’ 
– TTCGCGCTCTCGGCAGTG – 3’ (forward) and 5’ – TTCTTCTGCCAGTCACTTCCTACCC – 3’ (reverse). 
The PCR mixture contained 300 ng of genomic DNA, 0.2 mM dNTP , and 0.4PM of specific primers 
in PCR buffer solution in a 50POILQDOYROXPH5HDFWLRQZDVKRWVWDUWHGDW&IRUPLQXQLWV
of Taq polymerase was added and amplification carried out for 35 cycles (1 min at 94oC, 1 min at 
65o&DQGPLQDW&IROORZHGE\DILQDOH[WHQVLRQIRUPLQDW&7HQPl of each PCR reac-
tion was directly loaded onto 1.6% agarose gels, stained with ethidium bromide and visualised under 
UV illumination. PCR products were then purified and sequenced (DNA sequencer ABI 310, Applied 
Biosystems) with the same primers as those in PCR.
The data reveal one Leu
10Pro heterozygous and two Leu
10 homozygous BC patients relative 
to one Leu
10 homozygous HD and two Leu
10Pro heterozygous HD. Our results indicate the 
presence of Leu
10Pro or Leu
10YDULDQWVLQERWKVWDJH,,,SDWLHQWVDQGKHDOWK\GRQRUVEXWQRW
the Pro
10 variant responsible for the increased TGF-B1 secretion (9,11). The obtained geno-
type for an early BC and HD might explain unchanged TGF-B1 secretion in plasma of these 
subjects. Although obtained on small number of subjects, our results suggest that plasma 
TGF- B1 levels may not warrant it as useful biomarker for early BC stages. 
TGF-B1 SIGNALING PATHWAYS
During the past 4-5 years, there have been some important advances in the understanding 
of postreceptor signal transduction for TGF-ß1 (5). Currently, two signalling mechanisms 
have been identified including the Smad-mediated TGF-ß1 pathway and the mitogen-acti-
vated protein kinase (MAPK) pathway (4). Generally, these pathways are less complex than 
expected and involve finite number molecules including TGF-ß1 ligand, TGF-ß receptors 
and intracellular mediators that convey signals directly from cell-surface receptors to gene 
transcription sites.    
The molecular mechanism of Smad-mediated pathway has been completely elucidated. It 
involves TERI, TERII, Smad2, Smad3, and Smad4 as intracellular mediators in the following ZZZRQNQVDF\X$UFKLYH'HFHPEHU
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cascade of events: The TGF-B1 ligand binds to TERII directly. Once bound to the ligand,
TERII recruits, binds, and transphosphorylates TERI, thereby stimulating its protein kinase 
activity. The activated TERI phosphorylates intracellular transducer Smad2 (or Smad3), 
which binds to Smad4. The resulting Smad complex translocates into the nucleus and 
interacts in a cell-specific manner with transcription factors to regulate specifically the 
transcription of a multitude of TGF-E-responsive genes. TGF-E1 signalling is regulated by 
the level and duration of TERII receptor activation (5).
Current evidence suggests that MAPK signalling pathway involves transcription factors 
VXFK DV F)26F-81 FRPSOH[HV ZKLFK PHGLDWH 7*)E1 autoinduction (13). Other 
molecular details of the MAPK pathway are not elucidated yet (4). There are suggestions 
that activation of both Smad and MAPK pathways depends on the amount of input from 
the TERII receptor and that decreased TERII receptor expression changes the relative flux 
through the two parallel pathways. Moreover, it has been speculated that balance between 
TGF-ß1 tumour suppressor and tumour promoter activities depend on crosstalk between 
Smad and MAPK pathways (4).
POTENTIAL CLINICAL APPLICABILITY OF TGF-ß1 IN BREAST CANCER
The ability to define alterations in the TGF-ß1 signalling pathways at a molecular level in an 
individual’s tumour will allow the matching of targeted therapies developed for these altera-
tions to make individualized cancer treatment a less toxic and more effective reality (5). 
Current findings suggest that selective cancer-specific somatic mutations of Smad-medi-
ated signalling pathway might be responsible for the observed TGF-ß1 overexpression in 
advanced stages of various malignancies. As examples, four of the most prevalent human 
cancers have been selected: BC, cancer of the prostate, lung , and colon with mutational 
analysis of their Smad-mediated components presented in Table 2. The data reveal that in 
BC, decreased TßRII receptor expression was observed as well as rare TßRII gene muta-
tions, but no mutations in Smad2 and Smad4 genes were detected (Table 2).
Table 2. Mutation of Components of the Smad-mediated TGF-E1 Signaling Pathway  in Cancer (**)
Cancer TERII Gene Smad2 Gene Smad4 Gene
Breast
Frequently downregulated, 
rarely mutated
No mutations 
detected in ~100%
No mutations 
detected in ~ 100%
Prostate
TERII protein not detected 
in 24%
No mutation detected 
in ~ 100%
No mutation 
detected in ~ 100%
Lung
Frequently downregulated, 
rarely mutated
Mutated in 2% Mutated in 7%
Colon Mutated in 58-82% Mutated in 6% Mutated in 20%
** Modiffied from Elliott and Blobe (5)
Likewise, in prostate cancer (another hormonal tumour), complete loss of TßRII protein was 
observed in 24% cases and also no mutations in Smad2 and Smad4 genes were detected 
(Table 2). Whereas, in lung cancer the decreased expression of TERII receptor and muta-
tions of the Smad2 (2%) and Smad4 (7%) genes were observed. In contrast, colon cancer 
reveals selective mutations of the TERII receptor, which result in a non-functional receptor in 
RIWKHFDVHVDQGPXWDWHGSDUWLDOO\LQDFWLYDWLQJ6PDGDQGPXWDWHGRUGHOHWHG
Smad4 (20%) genes (Table 2). Thus, in the clinical scenarios involving decreased receptor 
expression, an increased expression of the receptor may be a reasonable therapeutic target 
with variety of agents such as bortezomib etc. These agents potentially could be used in 
conjunction with standard adjuvant therapy for BC, which exhibits frequently decreased 
TßRII levels (5).   
Numerous studies have revealed the potential clinical prognostic or predictive utility of TGF-ß1
or TERII levels (4,5). Among others, the tumour promoting role of TGF-ß1  has been supported 
by the demonstration of increased TGF-ß1 levels in human BC - production is increased with 
advanced stages of tumour (14); decreased TGF-ß1 levels  after surgical resection (15); per-
sistently elevated levels after surgical resection are in correlation with lymph node metastasis 
or residual tumour (15); and elevated TGF-ß1 levels conferring a poorer prognosis for BC 
patients (16). Consistent with these findings, we have previously determined significantly 
elevated plasma TGF-ß1 levels in advanced BC patients (12). Moreover, we have observed that 
this elevation was correlated with decreased survival of metastatic BC patients, thus providing 
direct evidence that plasma TGF-ß1 is a biomarker of a poor prognosis (17). Therefore, in 
clinical scenarios involving increased TGF-ß1 activity, attempts to decrease or abrogate TGF-ß1
signalling could be used as a therapy for advanced or metastatic disease. Attempts to block 
the effects of excessive TGF-ß1 activity has so far involved agents that inhibit TGF-ß1-binding 
to its receptor including natural TGF-ß1 inhibitors (e.g., decorin), neutralizing TGF-ß1 antibod-
ies, and soluble extracellular domain of TERII receptor (4).
CONCLUSION
TGF-ß1 has a complex multifunctional profile, with tumour suppressive effects in early 
stages of breast carcinogenesis, but progressive dominance of tumour promoting effects 
with transition to more advanced malignant states. Clarification of molecular mechanisms 
that control parallel processing of these opposing TGF-ß1 activities might suggest new 
approaches for shifting the balance in favour of net tumour suppression (18). Currently, a 
major challenge remains in more precisely defining TGF-ß1 signalling pathways. 
Although Smad-mediated TGF-ß1 signalling is well established, the mechanisms of 
MAPK signalling and other pathways remain to be elucidated. Once these pathways are 
established, more specific targeting of the TGF-ß1 signal-related components will be pos-
sible. Consequently, further research involving the manipulation of TGF-ß1 expression in a 
temporal and stage-dependent manner will help elucidate how and when therapeutic agents 
should be applied for chemoprevention and treatment of an early BC and whether anti-TGF-
ß1 strategies are more appropriate for the metastatic disease. 
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